Desorption of artemisinin extracts of CIM-Arogya by supercritical carbon dioxide

Artemisinin is a drug for chloroquine resistant malaria and cerebral malaria treatments. In the recent past, there was an acute shortage of this drug and hence World Health Organization made a strategy to fulfil the Artemisinin demand. In this study, artemisinin was extracted by supercritical Carbon Dioxide (SFCO2) from CIM-Arogya, a variety of Artemisia annua, in temperature and pressure ranges of 313.1-333.1 K and 15\u201325 MPa. Artemisinin global yield isotherms were determined obtaining a maximum yield of 3.65 wt%. Artemisinin extracts were also obtained by hexane Soxhlet extraction: then, the crude extracts were purified using SFCO2, after adsorption on silica gel. Different desorption runs were performed with a 6 ml/min CO2 flow rate, in temperature and pressure ranges of 313.1\u2013333.1 K and 15\u201325 MPa. At different time intervals, extracts were collected and analysed: their yields varied from 2.75% to 4.34% function of the experimental conditions. Desorption trials were also correlated with different models

Design of an Innovative Graphite Exchanger for Adsorption Heat Pumps and Chillers

Abstract In this work, an innovative adsorber for application in adsorption heat pumps and chillers is presented. The adsorber consists of several assembled graphite plates and the flow path of heat transfer fluid. Each plate consists of a process side (where zeolite is deposited onto) and a heat transfer fluid (HTF) side where liquid water flows. The resulting adsorbent heat exchanger is able to deliver about 0.5-1 kW cooling power and possesses attractive thermo physical properties, especially in term of low weight, volume and thermal capacity. Experimental testing of the full-scale adsorber by a testing station available at CNR ITAE is currently ongoing

Characterisation of IL‐1 family members in Sweet syndrome highlights the overexpression of IL‐1β and IL‐1R3 as possible therapeutic targets

Sweet syndrome (SS) as a prototypic neutrophilic dermatosis (NDs) shares certain clinical and histologic features with monogenic auto-inflammatory disorders in which interleukin (IL)-1 cytokine family members play an important role. This has led to the proposal that NDs are polygenic auto-inflammatory diseases and has fuelled research to further understand the role of IL-1 family members in the pathogenesis of NDs. The aim of this study was to characterise the expression of the IL-1 family members IL-1β, IL-36γ, IL-33 and IL-1R3 (IL-1RaP) in SS. The expression profile of IL-1β, IL-33, IL-36γ and their common co-receptor IL-1R3 was analysed by immunohistochemistry, in situ hybridisation and double immunofluorescence (IF) in healthy control skin (HC) and lesional skin samples of SS. Marked overexpression of IL-1β in the dermis of SS (p < 0.001), and a non-significant increase in dermal (p = 0.087) and epidermal (p = 0.345) IL-36γ expression compared to HC was observed. Significantly increased IL-1R3 expression within the dermal infiltrate of SS skin samples (p = 0.02) was also observed, whereas no difference in IL-33 expression was found between SS and HC (p = 0.7139). In situ hybridisation revealed a good correlation between gene expression levels and the above protein expression levels. Double IF identifies neutrophils and macrophages as the predominant sources of IL-1β. This study shows that IL-1β produced by macrophages and neutrophils and IL-1R3 are significantly overexpressed in SS, thereby indicating a potential pathogenic role for this cytokine and receptor in SS

Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma

Pathogenetic mechanisms of hepatocellular carcinoma (HCC) are stil unclear and new tools for diagnostic and therapeutic purposes are ongoing. We have assessed whether squamous cell carcinoma antigen (SCCA), a serpin overexpressed in neoplastic cells of epithelial origin, is also expressed in liver cancer. Squamous cell carcinoma antigen was evaluated by immunohistochemistry in 65 HCCs of different aetiology and in 20 normal livers. Proliferative activity was assessed using MIB-1 antibody. In 18 surgical samples, tumour and nontumour liver tissue was available for SCCA cDNA amplification and sequencing. Squamous cell carcinoma antigen was detected in 55 out of 65 (85%) tumour specimens, but in none of the 20 controls. In the majority of the cases, the positive signal was found in the cytoplasm of more than 50% of the hepatocytes. Low or undetectable SCCA (score less than or equal to1) was associated to lower MIB-1 labelling index, compared to cases with SCCA score greater than or equal to2 (mean +/-s.d.: 2%+/-2.4 vs 7.5%+/-10.3, P<0.05). Squamous cell carcinoma antigen mRNA could be directly sequenced in 14 out of 18 liver tumours but in none of the corresponding nontumour samples. From sequence alignment, a novel SCCA1 variant (G(351) to A) was identified in five cases, while SCCA1 was revealed in six cases and SCCA2 in three cases. In conclusion, SCCA variants are overexpressed in HCC, independently of tumour aetiology. A novel SCCA1 variant has been identified in one third of liver tumours

application of externally bonded inorganic matrix composites to existing masonry structures

Fabric-reinforced cementitious matrix (FRCM) and composite-reinforced mortar (CRM) are recently introduced inorganic-matrix composites that have shown promising results as externally bonded reinforcement (EBR) of existing masonry structures. FRCM and CRM comprised high-strength fiber textiles embedded within inorganic matrices. Different fibers and matrices can be used, which lead to a large number of systems characterized by different properties. In this paper, different techniques employed to strengthen the existing masonry structures with EBR. FRCM and CRM composites are presented and discussed

Entanglement entropy in a periodically driven Ising chain

In this work we study the entanglement entropy of a uniform quantum Ising chain in transverse field undergoing a periodic driving of period \u3c4. By means of Floquet theory we show that, for any subchain, the entanglement entropy tends asymptotically to a value \u3c4-periodic in time. We provide a semi-analytical formula for the leading term of this asymptotic regime: It is constant in time and obeys a volume law. The entropy in the asymptotic regime is always smaller than the thermal one: because of integrability the system locally relaxes to a generalized Gibbs ensemble (GGE) density matrix. The leading term of the asymptotic entanglement entropy is completely determined by this GGE density matrix. Remarkably, the asymptotic entropy shows marked features in correspondence to some non-equilibrium quantum phase transitions undergone by a Floquet state analog of the ground state

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

open24noTafamidis is a transthyretin (TTR) stabilizer able to prevent TTR tetramer dissociation. There have been a few encouraging studies on Tafamidis efficacy in early-onset inherited transthyretin amyloidosis (ATTR) due to Val30Met mutation. However, less is known about its efficacy in later disease stages and in non-Val30Met mutations. We performed a multi-center observational study on symptomatic ATTR patients prescribed to receive Tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years. Sixty-one (42 males) patients were recruited. Only 28 % of enrolled subjects had the common Val30Met mutation, mean age of onset was remarkably late (59 years) and 18 % was in advanced disease stage at study entry. Tafamidis proved safe and well-tolerated. One-third of patients did not show significant progression along 36 months, independently from mutation type and disease stage. Neurological function worsened particularly in the first 6 months but progression slowed significantly thereafter. Autonomic function remained stable in 33 %, worsened in 56 % and improved in 10 %. Fifteen percent of patients showed cardiac disease progression and 30 % new onset of cardiomyopathy. Overall, Tafamidis was not able to prevent functional progression of the disease in 23 (43 %) subjects, including 16 patients who worsened in their walking ability and 12 patients who reached a higher NYHA score during the follow-up period. A higher mBMI at baseline was associated with better preservation of neurological function. In conclusion, neuropathy and cardiomyopathy progressed in a significant proportion of patients despite treatment. However, worsening of neurological function slowed after the first 6 months and also subjects with more advanced neuropathy, as well as patients with non-Val30Met mutation, benefited from treatment. Body weight preservation is an important favorable prognostic factor.openCortese, A.; Vita, G.; Luigetti, M.; Russo, M.; Bisogni, G.; Sabatelli, M.; Manganelli, F.; Santoro, L.; Cavallaro, T.; Fabrizi, G.M.; Schenone, A.; Grandis, M.; Gemelli, C.; Mauro, A.; Pradotto, L.G.; Gentile, L.; Stancanelli, C.; Lozza, A.; Perlini, S.; Piscosquito, G.; Calabrese, D.; Mazzeo, A.; Obici, L.; Pareyson, DCortese, Andrea; Vita, G.; Luigetti, M.; Russo, M.; Bisogni, G.; Sabatelli, M.; Manganelli, F.; Santoro, L.; Cavallaro, T.; Fabrizi, G. M.; Schenone, A.; Grandis, M.; Gemelli, C.; Mauro, A.; Pradotto, L. G.; Gentile, L.; Stancanelli, C.; Lozza, A.; Perlini, Stefano; Piscosquito, G.; Calabrese, D.; Mazzeo, A.; Obici, L.; Pareyson, D